IGF-1, Sarcopenia and Mortality: a Cohort Study in Patient With Cognitive Impairment
Completed
- Conditions
- Cognitive ImpairmentInsulin-like Growth Factor 1
- Interventions
- Procedure: IGF-1 serum value
- Registration Number
- NCT02139410
- Lead Sponsor
- University of Roma La Sapienza
- Brief Summary
Insulin-like growth factor 1 (IGF)-1 is an important neuromyotrophic hormone. Disregulation of this hormone has been reported to influence the genesis of cognitive impairment and dementia in the elderly patients. We analyzed the possible link between IGF-1 and risk of Sarcopenia and Mortality in a cohort of elder patients with cognitive impairment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 589
Inclusion Criteria
- Diagnosis of cognitive impairment (MMSE < 24)
- Age > 65 ys
Exclusion Criteria
- Diagnosis of pancreatic disorders
- Diagnosis of acromegaly
- Diagnosis of GH-related disorders
- Recent bone fractures or immobility before the enrollment (3 months)
- Cancer
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description IGF-1 1st and 2nd quartile IGF-1 serum value Reduction of IGF-1 serum value in a cohort of patients with cognitive impairment IGF-1 3rd and 4rd quartile IGF-1 serum value Reduction of IGF-1 serum value in a cohort of patients with cognitive impairment
- Primary Outcome Measures
Name Time Method IGF-1 reduction in patients with sarcopenia baseline, 24 months, 48 months IGF-1 reduction could be linked to sarcopenia in patients with cognitive impairment
- Secondary Outcome Measures
Name Time Method IGF-1 reduction and mortality in patients with cognitive impairment baseline, 24 months, 48 months IGF-1 could be an independent risk factor for mortality in patients with cognitive impairment
Trial Locations
- Locations (2)
IRCCS Galeazzi
🇮🇹Milan, Italy
Sapienza University of Rome
🇮🇹Rome, Italy